Mercados
Préstamos
Earn
Invertir
VIP
Seguridad
Newsroom
Más
Iniciar sesión
Registrarse
Mercados
Resumen de mercados
Índices y commodities.
Digital Credit
Preferentes de Bitcoin Treasuries.
Acciones de IA
La temática de inteligencia artificial.
Bitcoin Treasuries
Empresas que tienen bitcoin.
Economía
Sectores, mercados globales y tasas.
Portafolios populares
Reportes 13F, smart money.
Préstamos
Pedir prestado
Pide prestado USDT o USDC con tu BTC como garantía, sin venderlo.
ReFi
Pasa tu préstamo respaldado por bitcoin a Roxom y paga menos interés.
Earn
Carry Trade
Pide prestado, invierte, quédate con el spread.
Dividendos de acciones
Pagados por acciones tokenizadas.
Invertir
VIP
Seguridad
Newsroom
Más
Empresa
Sobre nosotros
Nuestro equipo directivo, misión e inversores.
Whitepaper
La visión, el propósito y la arquitectura de Roxom.
Legal
Términos, privacidad y avisos legales.
Recursos
Centro de ayuda
Guías, preguntas frecuentes y soporte.
Estado del servicio
Estado operativo de la plataforma e incidentes.
Gráfico
Finanzas
Resultados
Noticias
Acerca de
Dividendos
Insiders
Reportes
BTC
SATS
USD
1d
1s
1m
6m
YTD
1a
5a
Todo
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Gráfico
Finanzas
Resultados
Noticias
Acerca de
Dividendos
Insiders
Reportes
BTC
SATS
USD
1d
1s
1m
6m
YTD
1a
5a
Todo
Loading chart
0R
0RV2.LSE
0R
BioArctic AB Series B
0RV2.LSE
Noticias
·
Eisai increases the number of participants in Clarity AD study
Cap. mercado
$8.24B
Volumen
759
Próximos resultados
November 25th
Gráfico
Finanzas
Resultados
Noticias
Acerca de
Dividendos
Insiders
Reportes
Eisai increases the number of participants in Clarity AD study
STOCKHOLM, Feb. 3, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately 200 in the pivotal Phase 3 study, Clarity AD, of drug candidate lecanemab (BAN2401) for t…
finance.yahoo.com · Feb 3, 2021
Eisai increases the number of participants in Clarity AD study
STOCKHOLM, Feb. 3, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have increased the participant target number by approximately 200 in the pivotal Phase 3 study, Clarity AD, of drug candidate lecanemab (BAN2401) for t…
finance.yahoo.com · Feb 3, 2021
Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020
STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- BioArctic AB (publ) [Nasdaq Stockholm: BIOA B] announced today data on the drug candidate BAN2401 (lecanemab), which were presented by the company's partner Eisai at the Clinical Trials on Alzheimer's Disease conference (CTAD), November 4-7…
finance.yahoo.com · Nov 9, 2020
Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020
STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- BioArctic AB (publ) [Nasdaq Stockholm: BIOA B] announced today data on the drug candidate BAN2401 (lecanemab), which were presented by the company's partner Eisai at the Clinical Trials on Alzheimer's Disease conference (CTAD), November 4-7…
finance.yahoo.com · Nov 9, 2020
BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference
STOCKHOLM, Oct. 28, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai will conduct four oral presentations related to the drug candidate BAN2401 (lecanemab) at the 13th Clinical Trials on Alzheimer's Disease Confe…
finance.yahoo.com · Oct 28, 2020
BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference
STOCKHOLM, Oct. 28, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai will conduct four oral presentations related to the drug candidate BAN2401 (lecanemab) at the 13th Clinical Trials on Alzheimer's Disease Confe…
finance.yahoo.com · Oct 28, 2020
BioArctic winner of the Allbright Award 2020
STOCKHOLM, Oct. 15, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its focused work with gender equality. The announcement was made on October 15 during Allbright's annual award ce…
finance.yahoo.com · Oct 15, 2020
BioArctic winner of the Allbright Award 2020
STOCKHOLM, Oct. 15, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its focused work with gender equality. The announcement was made on October 15 during Allbright's annual award ce…
finance.yahoo.com · Oct 15, 2020
Invitation to presentation of BioArctic's Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET
STOCKHOLM, Oct. 6, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - September 2020 on Wednesday, October 14, 2020, at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in Engl…
finance.yahoo.com · Oct 6, 2020
Invitation to presentation of BioArctic's Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET
STOCKHOLM, Oct. 6, 2020 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - September 2020 on Wednesday, October 14, 2020, at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in Engl…
finance.yahoo.com · Oct 6, 2020
Tenencias
Órdenes abiertas (0)
Posiciones (0)
Historial de órdenes
Dividendos
Transferencias
Iniciar sesión
para empezar a operar
0R
0RV2.LSE
BioArctic AB Series B
Comprar
Vender
Mercado
Límite
Pronto
0RV2.LSE
25%
50%
75%
Máx.
Pagar con
—
Empezar a operar
Saldo disponible
0,00
Tu posición
Aún no tienes 0RV2.LSE.
Tickers relacionados
Resultados
Dividendos
Último · May 29
Importe
$2.00
Rendimiento
0.69%
Anual
$2.00